Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2948.

https://doi.org/10.1182/blood-2019-124343

Published: 2019

Journal Articles

Specific and Targetable Interactions with the Bone Marrow Microenvironment Govern Outcome in Imatinib-Resistant Chronic Myeloid Leukemia

Rahul Kumar, PhD, Maximilian Marten, Bachelors, Valentina Minciacchi, PhD, Raquel Pereira, M.Sc, Costanza Zanetti, MSc, Nina Hyduk, M.Sc, Thomas Oellerich, MD, Hans Michael Kvasnicka, MD, Joel Spencer, PhD, Frank Schnuetgen, PhD, Charles Lin, PhD, Cristina Lo Celso, PhD, Melanie Meister, PhD, Franck Emmanuel Nicolini, MD PhD, Daniela S. Krause, MD

Blood (2018) 132 (Supplement 1): 936.

https://doi.org/10.1182/blood-2018-99-111827

Published: 2018

Journal Articles

Heterogeneity of Bone Marrow Morphology in Patients with Polycythemia Vera Resistant to First and Second Line Therapies - Impact of Hydroxyurea Dosage on MDS-like Progression

Hans Michael Kvasnicka, Gina Liviana Frank, Marlene Lemp, Fabian Lang, MD, Juergen Thiele, MD

Blood (2017) 130 (Supplement 1): 2913.

https://doi.org/10.1182/blood.V130.Suppl_1.2913.2913

Published: 2017

Journal Articles

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Ahmad Naim, MD, Smitha Svaraman, PhD, Jessy Gao, MA, Jason R. Gotlib, MD, Vikas Gupta, MD FRCP, FRCPath, Kim-Hien Dao, DO, PhD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 1949.

https://doi.org/10.1182/blood.V128.22.1949.1949

Published: 2016

Journal Articles

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Jorge E. Cortes, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3182.

https://doi.org/10.1182/blood.V124.21.3182.3182

Published: 2014

Journal Articles

Changes in Activated Bone Marrow Macrophages and Mast Cells in Patients with Myelofibrosis Following Ruxolitinib Therapy

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MDPhD, Carlos E. Bueso-Ramos, MD PhD, Shilpa Kamalanabhaiah, Jorge E. Cortes, MD, Hagop Kantarjian, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3184.

https://doi.org/10.1182/blood.V124.21.3184.3184

Published: 2014

Journal Articles

Ruxolitinib Therapy Effectively Modulates CD34 + Hematopoietic Progenitors and Bone Marrow Angiogenesis in Patients with Myelofibrosis

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MDPhD, Carlos E. Bueso-Ramos, MD PhD, Shilpa Kamalanabhaiah, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 4578.

https://doi.org/10.1182/blood.V124.21.4578.4578

Published: 2014

Journal Articles

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Nicolaus Kröger, MD, Haefaa Alchalby, MD, Tatjana Zabelina, MD, Hans-Michael Kvasnicka, MD, Juergen Thiele, MD, PhD, Guntram Büsche, MD, Hans Kreipe, MD

Blood (2013) 122 (21): 2078.

https://doi.org/10.1182/blood.V122.21.2078.2078

Published: 2013

Journal Articles

Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy

Hans Michael Kvasnicka, MD, PhD, Jürgen Thiele, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, William Sun, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4055.

https://doi.org/10.1182/blood.V122.21.4055.4055

Published: 2013

Journal Articles

Effects Of Ruxolitinib Therapy On Megakaryocyte Morphology and Inflammatory Bone Marrow Reaction In Patients With Myelofibrosis

Hans Michael Kvasnicka, MD, PhD, Juergen Thiele, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, Shilpa Kamalanabhaiah, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4056.

https://doi.org/10.1182/blood.V122.21.4056.4056

Published: 2013

Journal Articles

Correlation Of Longitudinal Blood Counts With Thromboembolic Complications In WHO 2008 Defined Prefibrotic Primary Myelofibrosis

Veronika Buxhofer-Ausch, Martin Schalling, Sophie Frantal, Jürgen Thiele, MD, PhD, Leonhard Muellauer, M.D., Hans-Michael Kvasnicka, MD, Bettina Gisslinger, Heinz Gisslinger, MD

Blood (2013) 122 (21): 2834.

https://doi.org/10.1182/blood.V122.21.2834.2834

Published: 2013

Journal Articles

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

Heinz Gisslinger, Mirjana Gotic, Jerzy Holowiecki, Miroslav Penka, Juergen Thiele, Hans-Michael Kvasnicka, Robert Kralovics, Petro E. Petrides

Blood (2013) 121 (10): 1720–1728.

https://doi.org/10.1182/blood-2012-07-443770

Published: 2013

Includes: Supplemental data

Journal Articles

Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor

Nina Reinart, Phuong-Hien Nguyen, Jorge Boucas, Natascha Rosen, Hans-Michael Kvasnicka, Lukas Heukamp, Cornelia Rudolph, Vangica Ristovska, Tanja Velmans, Carolin Mueller, Katrin S. Reiners, Elke Pogge von Strandmann, Günter Krause, Manuel Montesinos-Rongen, Brigitte Schlegelberger, Marco Herling, Michael Hallek, Günter Fingerle-Rowson

Blood (2013) 121 (5): 812–821.

https://doi.org/10.1182/blood-2012-05-431452

Published: 2013

Includes: Supplemental data

Journal Articles

Decanucleotide Insertion Polymorphism of F7 Influences Significantly the Risk of Thrombosis in Patients with Essential Thrombocythemia

Veronika Buxhofer-Ausch, Damla Olcaydu, Bettina Gisslinger, Martin Schalling, Sophie Frantal, Juergen Thiele, Leonhard Müllauer, Hans-Michael Kvasnicka, Robert Kralovics, Heinz Gisslinger

Blood (2012) 120 (21): 1730.

https://doi.org/10.1182/blood.V120.21.1730.1730

Published: 2012

Journal Articles

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

Blood (2012) 120 (6): 1197–1201.

https://doi.org/10.1182/blood-2012-01-403279

Published: 2012

Includes: Supplemental data

Journal Articles

A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Blood (2011) 118 (21): 1746.

https://doi.org/10.1182/blood.V118.21.1746.1746

Published: 2011

Journal Articles

Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm

Alessandra Carobbio, MSc, Guido Finazzi, MD, Juergen Thiele, Hans-Michael Kvasnicka, Francesco Passamonti, MD, Elisa Rumi, Marco Ruggeri, MD, Francesco Rodeghiero, MD, Maria Luigia Randi, Irene Bertozzi, Alessandro M. Vannucchi, MD, Elisabetta Antonioli, Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, Naseema Gangat, MD, Alessandro Rambaldi, Ayalew Tefferi, MD, Tiziano Barbui, MD

Blood (2011) 118 (21): 5148.

https://doi.org/10.1182/blood.V118.21.5148.5148

Published: 2011

Journal Articles

Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients,

Blood (2011) 118 (21): 3846.

https://doi.org/10.1182/blood.V118.21.3846.3846

Published: 2011

Journal Articles

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

Blood (2011) 118 (21): 1019.

https://doi.org/10.1182/blood.V118.21.1019.1019

Published: 2011

NARROW

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Specific and Targetable Interactions with the Bone Marrow Microenvironment Govern Outcome in Imatinib-Resistant Chronic Myeloid Leukemia

Heterogeneity of Bone Marrow Morphology in Patients with Polycythemia Vera Resistant to First and Second Line Therapies - Impact of Hydroxyurea Dosage on MDS-like Progression

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

Changes in Activated Bone Marrow Macrophages and Mast Cells in Patients with Myelofibrosis Following Ruxolitinib Therapy

Ruxolitinib Therapy Effectively Modulates CD34 + Hematopoietic Progenitors and Bone Marrow Angiogenesis in Patients with Myelofibrosis

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy

Effects Of Ruxolitinib Therapy On Megakaryocyte Morphology and Inflammatory Bone Marrow Reaction In Patients With Myelofibrosis

Correlation Of Longitudinal Blood Counts With Thromboembolic Complications In WHO 2008 Defined Prefibrotic Primary Myelofibrosis

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor

Decanucleotide Insertion Polymorphism of F7 Influences Significantly the Risk of Thrombosis in Patients with Essential Thrombocythemia

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm

Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients,

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only